Peptide Biologix
Compound index
The atlas

MGF (Mechano Growth Factor)

Mechano Growth Factor (MGF) is the C-terminal E-domain splice variant of insulin-like growth factor-1 (IGF-1Ec) expressed in skeletal muscle in response to mechanical loading or tissue stretch.

Watercolour seaweed study with undulating kelp blades and a small holdfast
Plate 20MGF
AA Sequence Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys
Regulatory & Compounding Status (April 2026)

MGF (Mechano Growth Factor) is not an FDA-approved human or veterinary drug product and has not been evaluated for clinical therapeutic use. Synthetic MGF C-terminal fragments are supplied strictly as analytical reference standards and in vitro / preclinical laboratory reagents.

Molecular Properties

Parameter Value
Chemical Name Mechano Growth Factor / IGF-1Ec
Amino Acid Sequence Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-Cys
Molecular Formula C121H200N42O39
Molecular Weight 2948.15 g/mol
CAS Number Not assigned (research peptide)
Sequence Length 25 amino acids (C-terminal splice variant of IGF-1)
Isoform Type IGF-1Ec splice variant (exon 5 included)

Physical Properties

Property Specification
Appearance White to off-white sterile-filtered lyophilized powder
Solubility Soluble in sterile water or bacteriostatic water at ≥0.5 mg/mL; optimal at pH 7.0–8.0
pH (1% solution) 6.5 – 7.5
Hygroscopicity Low to moderate; desiccated storage recommended
Solution Stability Stable at 4°C for 5–7 days; degradation accelerates at room temperature

Analytical Specifications

Test Specification
HPLC Purity ≥98.0%
Mass Spectrometry Confirmed [M+H]+ = 2948.15 ± 1.0 Da
Peptide Content ≥90% (by UV absorbance at 280 nm)
Endotoxin Level <1.0 EU/mg
Acetate Content ≤8%
TFA Content ≤0.5%
Water Content ≤10% (Karl Fischer)

Storage Parameters

Condition Specification
Lyophilized Storage −20°C, desiccated with desiccant packet
Lyophilized Shelf Life 24 months when stored properly at −20°C
Reconstituted Storage 2–8°C for up to 7 days; −20°C for up to 2 months
Freeze-Thaw Cycles Maximum 2–3 cycles; single-use aliquots strongly recommended
Light Sensitivity Minimal; standard laboratory storage acceptable

In Vitro & Preclinical Model Concentrations

Literature summary of published study doses, routes, and schedules.
Application Typical Dose Range Frequency Route
In Vitro Myoblast Studies 10–100 ng/mL (3.4–34 nM) Single treatment or daily media change Culture media
Small Animal Models (Rodent) 50–200 μg/kg Daily or post-exercise SC or IM injection
Muscle Repair Studies 100–500 μg/kg 3–5x per week for 2–4 weeks IM at injury site
Satellite Cell Activation 25–100 ng/mL in vitro; 100 μg/kg in vivo Single dose or 24h intervals Local or SC

Note: Reference concentrations are documented strictly for laboratory research. MGF is not approved for human or veterinary use.

Key Research Studies

Literature summary of published study doses, routes, and schedules.
Year Study Focus Key Findings
1996 Discovery and characterization of MGF First identification of mechanically-induced IGF-1Ec splice variant in muscle tissue; expression peaks 2–4 hours post-exercise with unique C-terminal E-domain sequence
2003 Satellite cell activation mechanisms MGF demonstrated superior satellite cell activation compared to systemic IGF-1; 25–49 amino acid E-peptide domain responsible for unique proliferative effects independent of IGF-1R
2007 Muscle repair in injury models Local MGF injection (200 μg/kg) post-injury increased muscle fiber cross-sectional area by 25% vs controls; accelerated satellite cell proliferation detected within 48 hours
2014 Neuroprotective and angiogenic properties MGF treatment protected motor neurons from oxidative stress; upregulated VEGF expression and capillary density in ischemic muscle models with ED50 ~50 μg/kg

Mechanism of Action

Biological Pathway Description
Splice Variant Origin Alternative splicing of IGF-1 gene produces IGF-1Ec isoform; mechanical loading triggers exon 5 inclusion in muscle tissue
Satellite Cell Activation E-peptide domain activates quiescent satellite cells independent of IGF-1R; stimulates cell cycle entry and myoblast proliferation
Receptor Interactions Dual signaling: mature IGF-1 domain binds IGF-1R (PI3K/Akt pathway); E-peptide acts via separate, partially characterized receptor
Temporal Expression Rapid upregulation (2–4h) post-mechanical stimulus; precedes systemic IGF-1Ea expression (24–48h)
Half-Life ~5–7 minutes (IV); rapid proteolytic degradation; local paracrine action predominates (motivating PEG-MGF for systemic pharmacokinetic studies)

Quality Control Parameters

Test Method Acceptance Criteria
Appearance (visual) White to off-white cake or powder; no discoloration
Reconstitution Test Complete dissolution within 2 minutes; clear to slightly opalescent solution
RP-HPLC (purity) Main peak ≥98.0% by area; no single impurity >0.5%
ESI-MS (identity) Observed mass within ±0.05% of theoretical
LAL Endotoxin Test <1.0 EU/mg

Primary Scientific References

  1. Yang S, et al. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. J Muscle Res Cell Motil. 1996;17(4):487-495. https://pubmed.ncbi.nlm.nih.gov/8884603/
  2. Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology. 2005;20:232-238. https://journals.physiology.org/doi/full/10.1152/physiol.00004.2005
  3. Dai Z, et al. Mechanically overloaded skeletal muscles: Expression and splicing of IGF-I. Gene. 2010;491(2):185-190. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818379/